Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

692 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: rutkowski p. Nat Med. 2024 Feb;30(2):607. doi: 10.1038/s41591-023-02661-5. Nat Med. 2024. PMID: 37923838 Free PMC article. No abstract available.
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: rutkowski p. Nat Med. 2024 Mar;30(3):906. doi: 10.1038/s41591-023-02775-w. Nat Med. 2024. PMID: 38177857 Free PMC article. No abstract available.
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Kirkwood JM, Vecchio MD, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: rutkowski p. Future Oncol. 2024 May;20(15):959-968. doi: 10.2217/fon-2023-0977. Epub 2024 Feb 23. Future Oncol. 2024. PMID: 38390818 Free article. Review.
Lymphadenectomy in the treatment of sarcomas - indications and technique.
Dunaj P, Żukowska E, Czarnecka AM, Krotewicz M, Borkowska A, Chmiel P, Świtaj T, Rutkowski P. Dunaj P, et al. Among authors: rutkowski p. Oncol Rev. 2024 Dec 5;18:1413734. doi: 10.3389/or.2024.1413734. eCollection 2024. Oncol Rev. 2024. PMID: 39737200 Free PMC article. Review.
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.
Kandolf L, Ascierto PA, Bastholt L, Gavrilova I, Haanen J, Hauschild A, Herceg D, Hoeller C, Jalovcic Suljevic A, Kessels JI, Krajsova I, Kukushkina M, Lallas A, Lorigan P, Mangana J, Marquez-Rodas I, Mazilu L, Mohr P, Bylaite-Bucinskiene M, Ocvirk J, Olah J, Putnik K, Rutkowski P, Saiag P, Samolyenko I, Schwarze JK, Stojkovski I, Cicmil Sarić N, Vieira R, Weichenthal M, Garbe C. Kandolf L, et al. Among authors: rutkowski p. Eur J Cancer. 2024 Nov 16;216:115124. doi: 10.1016/j.ejca.2024.115124. Online ahead of print. Eur J Cancer. 2024. PMID: 39721295
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas H, Lao CD, Janoski De Menezes J, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Tawbi HA, et al. Among authors: rutkowski p. J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124. Online ahead of print. J Clin Oncol. 2024. PMID: 39671533
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.
Handel EE, McKeown J, Wei J, Kankaria RA, Burnette H, Johnson DB, Lawless A, Czapla J, Sullivan RJ, Albrecht LJ, Zimmer L, Mangana J, Dummer R, Kessels JI, Neyns B, Allayous C, Lebbe C, Boatwright C, Mehnert JM, Ottaviano M, Ascierto PA, Czarnecka AM, Rutkowski P, Lo SN, Long GV, Menzies AM, Carlino MS. Handel EE, et al. Among authors: rutkowski p. Eur J Cancer. 2025 Jan 17;215:115171. doi: 10.1016/j.ejca.2024.115171. Epub 2024 Dec 9. Eur J Cancer. 2025. PMID: 39667250
Comparing epidemiological and clinical data from RPS patients documented in a German cancer registry to a cohort from TARPSWG reference centres.
Neemann F, Jansen L, Hermann S, Silcher C, Hettler M, Hohenberger P, Callegaro D, Gronchi A, Fiore M, Miceli R, Van Coevorden F, Van Houdt W, Bonvalot S, Rutkowski P, Skoczylas J, Swallow CJ, Gladdy R, Strauss DC, Hayes A, Fairweather M, Raut CP, Jakob J. Neemann F, et al. Among authors: rutkowski p. J Cancer Res Clin Oncol. 2024 Nov 28;150(12):514. doi: 10.1007/s00432-024-06033-5. J Cancer Res Clin Oncol. 2024. PMID: 39604531 Free PMC article.
692 results